RT Journal Article SR Electronic T1 Implications of recurrent SARS-CoV-2 outbreaks for IBD management JF Frontline Gastroenterology JO Frontline Gastroenterol FD BMJ Publishing Group Ltd SP 316 OP 321 DO 10.1136/flgastro-2020-101531 VO 12 IS 4 A1 Segal, Jonathan P A1 Moss, Alan C YR 2021 UL http://fg.bmj.com/content/12/4/316.abstract AB The initial phases of the global SARS-CoV2 pandemic had significant implications for the management of patients with inflammatory bowel disease (IBD). This impact is likely to be sustained and far-reaching across all models of care. Initial questions about the risk of SARS-CoV2 infection, and COVID-19 complications, in patients taking maintenance anti-TNFs, JAK inhibitors and other immune modulators have preliminary data. Current models for SARS-CoV-2 transmission predict intermittent outbreaks until 2022, which could disrupt clinical care and negatively affect outcomes for many patients across the globe. This review summarises changes in IBD clinical practice that will be required during the ‘post-peak’ phase of viral pandemics.